[Proxodolol--a new beta- and alpha-adrenoblockader].
The beta- and alpha-adrenoceptor blocking activity, the specificity of its beta-adrenoceptor blocking action, partial agonistic and membrane-stabilizing properties, as well as antihypertensive, antiarrhythmic, and anti-ischemic effects were studied. Proxodolol was shown to be superior to labetalol in its beta-adrenoceptor blocking action and similar to it in its alpha-adrenoceptor blocking agent. The drug has no a partial agonistic activity and produces a moderate membrane-stabilizing action. Proxodolol proved to be effective in treating experimental hypertension and arrhythmias. It exhibits anti-ischemic activity.
Iuzhakov
S D
SD
Dolgun
O V
OV
Dorodnikova
E V
EV
Aniukhovskiĭ
E P
EP
Baldenkov
G N
GN
Rozenshtraukh
L V
LV
Medvedev
O S
OS
Mashkovskiĭ
M D
MD
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002415:Cats; D002462:Cell Membrane / Q000187:drug effects; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000188:drug therapy; D066298:In Vitro Techniques; D007741:Labetalol / Q000494:pharmacology; D008297:Male; D010069:Oxadiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D010096:Oxprenolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D051381:Rats
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D010069:Oxadiazoles; C088649:proxodolol; D010096:Oxprenolol; D011433:Propranolol; D007741:Labetalol
Proksodolol--novyĭ (beta-, al'fa-)adrenoblokator.